Testis-Sparing Surgery for Multiple Fibrous Pseudotumors of the Epididymis: A Case Report.

Am J Case RepOct 26, 2026 (epub)

Di Xue, Aijun Zhu, Huaijie Yang et al.

✦ AI-curated · Sources linked

Case in brief

A 44-year-old man had multiple firm, nontender left epididymal nodules. Ultrasound showed hypoechoic lesions without testicular invasion, and tumor markers were negative. At surgery, the masses were distinct from the testis and the tunica albuginea was intact, allowing complete testis-sparing resection without frozen section. Histology showed a fibroblastic and myofibroblastic proliferation with lymphoplasmacytic inflammation, consistent with fibrous pseudotumor; the IgG4/IgG ratio was below 40%. He recovered uneventfully, with no recurrence and normal testicular morphology and blood flow at follow-up.

What made this case unusual

The lesion arose in the epididymis and presented as multiple nodules, an uncommon origin for paratesticular fibrous pseudotumor. Their clear separation from the testis permitted complete resection while preserving it.

Diagnostic / clinical pearl

For multiple epididymal masses without testicular invasion, include fibrous pseudotumor in the differential. Intraoperative assessment of separation from the testis can support testis-sparing resection; frozen section may help when the diagnosis remains uncertain.

Source

Published in Am J Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.